IL1RL2 and psoriasis: In fact, blocking the IL-36 receptor has been already been shown to be a successful strategy in pre-clinical models of psoriasis [18], and clinical trials are ongoing to validate the safety and efficacy of this therapeutic approach in human [36, 37].